Categories Earnings, Health Care

AMAG Pharmaceuticals (AMAG) Q4 2019 Earnings Snapshot

— AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019 vs. $0.36 per share loss expected.

— During the fourth quarter, the company recorded impairment charges of $155 million.

Earnings Update by AlphaStreet

— Revenue increased to $89.7 million from $88.1 million last year vs. $88.39 million expected.

— For fiscal 2020, AMAG expects revenue to be between $230 million and $280 million. Non-GAAP adjusted EBITDA is expected to be in the range of $20 million to $50 million.

— 2020 key priorities include completing CEO transition, divest Intrarosa and Vyleesi, drive continued Feraheme growth and work with the FDA to maintain patient access to Makena.

— AMAG also announced today that its Chief Medical Officer Julie Krop will be leaving the company with effect from March 31, 2020. The Board has initiated the search for a permanent CMO.

— AMAG stock had retreated 24% in the past three months and 45% from this time last year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

COST Earnings: A snapshot of Costco’s Q4 2023 financial results

Costco Wholesale Corporation (NASDAQ: COST), which operates a chain of membership warehouses, on Tuesday reported results for the fourth quarter of fiscal 2024. The company posted revenues of $78.9 billion

What to look for when McCormick & Co. (MKC) reports Q3 2023 earnings

Shares of McCormick & Company Inc. (NYSE: MKC) were down on Tuesday. The stock has fallen 19% over the past three months. The spices and seasonings maker is scheduled to report its

Cintas Corporation (CTAS) Q1 2024 Earnings: Key financials and quarterly highlights

Cintas Corporation (NASDAQ: CTAS) reported first quarter 2024 earnings results today. Revenue was $2.34 billion, up 8.1% from the same period last year. Organic revenue growth was also 8.1%. Net

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top